- Acquired by Boston Scientific, Mar 2025
- Raised $60M funding round led by Andera Partners, Jan 2023
- Raised $9.8M funding round, Jan 2018
About
SoniVie is a medical device company developing a system for the treatment of pulmonary hypertension (PAH). The companys therapeutic intravascular ultrasound (TIVUS) is a dedicated therapeutic catheter that offers a treatment for PAH. The TIVUS catheter is inserted into the pulmonary artery in a catheterization procedure and selectively damages nerves associated with disease activity without touching the vessel walls or damaging the adjacent tissues. This treatment may significantly slow the disease progression. In March 2016, SoniVie successfully completed the first two procedures in its phase 1 multicenter clinical trial. The TIVUS system is currently approved for sale in markets regulated by the CE mark. In September 2019, the TIVUS system received a breakthrough device designation by the FDA for use in the treatment of pulmonary arterial hypertension, and in December 2020, the system received a breakthrough device designation for use in renal artery denervation for the treatment of resistant hypertension.
Funding history · 3 rounds · $73.3M total
Q&A
- What is SoniVie's primary business?
- SoniVie is a medical device company focused on developing a system for the treatment of pulmonary hypertension (PAH) using its therapeutic intravascular ultrasound (TIVUS) catheter.
- When was SoniVie acquired and by whom?
- SoniVie was acquired by Boston Scientific in March 2025.
- What was SoniVie's most recent funding round?
- In January 2023, SoniVie raised $60,000,000 in a funding round led by Andera Partners.
- Where is SoniVie's headquarters located?
- SoniVie's headquarters is located in Rosh Haayin, Israel.
- What breakthrough device designations has SoniVie received from the FDA?
- SoniVie's TIVUS system received a breakthrough device designation from the FDA in September 2019 for pulmonary arterial hypertension and in December 2020 for renal artery denervation for resistant hypertension.
- What is the status of SoniVie's TIVUS system approval?
- The TIVUS system is currently approved for sale in markets regulated by the CE mark.
- What is the total amount of funding SoniVie has raised to date?
- SoniVie has raised a total of $73,260,000.
Sectors & technology
Highlights
Tags
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | sonivie.com/ |
|---|
Identifiers & details
| Former names | Cardiosonic |
|---|---|
| Founded | 2014-8 |
| Employees (exact) | 7 |
| Offices | Saint Paul |
| Status reason | Acquired by Boston Scientific on Mar, 2025 |
Acquisitions & public offerings
Acquired by Boston Scientific 2025-03
Radar intelligence
Patents
| EPO | 9 |
|---|
Web history (Wayback)
| Domain | sonivie.com |
|---|
Certificate / subdomain footprint
| Subdomains | 2 |
|---|